Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01694966 · ClinicalTrials.gov registry record · Phase 3
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
A Phase 3 study, sponsored by Cosmo Technologies.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,249
- Enrollment target
NCT01694966 is a Phase 3 study that has completed, run by Cosmo Technologies. The registered enrollment target is 1,249 participants.
The verdict
NCT01694966, a Phase 3 study, has completed, sponsored by Cosmo Technologies.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,249 participants
- Enrollment target
Study Summary
Evaluation of the histologically proven adenoma and carcinoma detection rate in patients undergoing a full colonoscopy with and without mucosal contrast enhancement, obtained with 200 mg of Methylene Blue MMX® tablets.
Interventions
- DRUG Placebo
- DRUG Methylene Blue MMX®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,249 participants |
| Start Date | 2013-09 |
| Est. Completion | 2016-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01694966
The ClinicalTrials.gov registry entry for NCT01694966 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,249 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cosmo Technologies, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01694966 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01694966 about?
NCT01694966 is a clinical study titled "The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy". Evaluation of the histologically proven adenoma and carcinoma detection rate in patients undergoing a full colonoscopy with and without mucosal contrast enhancement, obtained with 200 mg of Methylene Blue MMX® tablets.
What is the current status of trial NCT01694966?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,249 participants. The study started on 2013-09. Estimated completion is 2016-10.
What interventions are being tested in trial NCT01694966?
The interventions under investigation include: Placebo (DRUG), Methylene Blue MMX® (DRUG).
Who is sponsoring clinical trial NCT01694966?
This trial is sponsored by Cosmo Technologies, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.